Epi­genic Ther­a­peu­tics en­ters crowd­ed glob­al gene ther­a­py mar­ket with $32M Se­ries A

Shang­hai-based Epi­genic Ther­a­peu­tics raised $32 mil­lion in a Se­ries A for two un­named gene ther­a­py pro­grams, the com­pa­ny an­nounced Wednes­day.

The com­pa­ny says it’s de­vel­op­ing gene mod­u­la­tion ther­a­pies us­ing epigenome reg­u­la­tion to treat preva­lent and chron­ic dis­eases. Epi­genic al­so has its Epireg plat­form, which us­es AI to find and get CRISPR-Cas com­po­nents to reg­u­late tar­get genes or the ex­pres­sion of mul­ti­ple genes at one time with­out chang­ing the DNA se­quence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER